Neoplasms Clinical Trial
Official title:
Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
Status | Recruiting |
Enrollment | 190 |
Est. completion date | September 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. 20 Years and older. 2. Life expectancy of at least 12 weeks at the pre-treatment evaluation. 3. Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or typical findings by dynamic CT or CT during hepatic arteriography/arterioportography. 4. Not suitable for resection or local ablation therapy or transcatheter arterial chemoembolization. 5. ECOG Performance status of 0 or 1. 6. Cirrhotic status of Child-Pugh score = 7. 7. Adequate bone marrow, liver and renal function, as assessed by the following laboratory requirements: - Hemoglobin =8.5 g/dl - Granulocytes=1500/µL - Platelet count =50,000 /µL - PT-INR = 2.3 - Total serum bilirubin = 2 mg/dl - AST(SGOT) and ALT(SGPT) = 6 × upper limit of normal - Serum creatinine = 1.5 × upper limit of normal - Amylase = 2 × upper limit of normal 8. Written Informed Consent must be obtained. Exclusion Criteria: 1. Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1], early gastric cancer, or other malignancies curatively treated > 3 years prior to entry 2. Renal failure 3. Any heart disease as follows - Congestive heart failure defined as NYHA class III or IV - Active coronary artery disease or ischemic heart disease such as cardiac infarction within 6 months prior to screening - Serious cardiac arrhythmia - Serious hypertension 4. Active clinically serious infections except for HBV and HCV 5. Active chicken pox. 6. Auditory disorder. 7. Known history of HIV infection. 8. Known metastatic or meningeal tumors. 9. Extrahepatic tumor spread which affects patient's prognosis 10. History of seizure disorder. 11. Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry. 12. Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization. 13. Any history of treatment as follows: - Treatment with the agent which induces CYP3A4 - Surgical procedure within 4 weeks prior to start of study drug - History of organ allograft 14. Patients unable to swallow oral medications. 15. Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics. 16. Medication that may affect to the absorption of drug or pharmacokinetics. 17. Any disease or disorder that may affect the evaluation of study drug. 18. Entry to the other clinical trial within 4 weeks prior to entry to this study. 19. Pregnant or breast-feeding patients. 20. Known allergy to the investigational agent or any agent given in association with this trial. 21. Substance abuse, medical, psychological or social conditions that, in the judgment of the investigator, is likely to interfere with the patient's participation in the study or evaluation of the stuy results. 22. Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Chiba University Hospital | Chiba | |
Japan | Gifu Municipal Hospital | Gifu | |
Japan | Hiroshima City Hospital | Hiroshima | |
Japan | Hiroshima University Hospital | Hiroshima | |
Japan | Ikeda Municipal Hospital | Ikeda | Osaka |
Japan | National Cancer Center Hospital East | Kashiwa | Chiba |
Japan | Kumamoto University Hospital | Kumamoto | |
Japan | Kawasaki Medical School Hospital | Kurashiki | Okayama |
Japan | Kurume University Medical Center | Kurume | Fukuoka |
Japan | Kyoto University Hospital | Kyoto | |
Japan | Kyorin University Hospital | Mitaka | Tokyo |
Japan | Center for Gastroenterological and Hepatological Diseases | Miyazaki | |
Japan | Musashino Red Cross Hospital | Musashino | Tokyo |
Japan | Juntendo University Nerima Hospital | Nerima | Tokyo |
Japan | Niigata University Medical and Dental Hospital | Niigata | |
Japan | Saiseikai Niigata Dai-ni Hospital | Niigata | |
Japan | Ogaki Municipal Hospital | Ogaki | Gifu |
Japan | National Hospital Organization Nagasaki Medical Center | Ohmura | Nagasaki |
Japan | Okayama University Hospital | Okayama | |
Japan | Osaka Red Cross Hospital | Osaka | |
Japan | Kinki University Hospital | Osaka-Sayama | Osaka |
Japan | Sapporo Medical University | Sapporo | Hokkaido |
Japan | Sapporo-Kosei General Hospital | Sapporo | Hokkaido |
Japan | Osaka University Hospital | Suita | Osaka |
Japan | Japanese Red Cross Takamatsu Hospital | Takamatsu | Kagawa |
Japan | The University of Tokushima Faculty of Medicine | Tokushima | |
Japan | Kyoundo Hospital | Tokyo | |
Japan | National Cancer Center Hospital | Tokyo | |
Japan | Mie University Hospital | Tsu | Mie |
Japan | Yamaguchi University Hospital | Ube | Yamaguchi |
Lead Sponsor | Collaborator |
---|---|
Ministry of Health, Labour and Welfare, Japan |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | Overall survival is defined as the time from randomization to death due to any cause | No | |
Secondary | Time to progression | TTP is defined as the time from randomization to radiological progression. | No | |
Secondary | Progression Free Survival | PFS is defined as the time from randomization to radiological progression or death due to any cause | No | |
Secondary | Change of tumor marker | Every 4-6 weeks | No | |
Secondary | Biomarker predicting the efficacy | Pre and after treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |